New drug BTX-A51 tested in rare sarcomas

NCT ID NCT06414434

Ongoing Disease control Sponsor: Michael Wagner, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 02, 2026 · Updated 4 times

Summary

This early study tests an oral drug called BTX-A51 in 24 people with advanced liposarcoma (a type of fat tissue cancer) that has spread or come back. The main goal is to see if the drug is safe and tolerable at different doses. It focuses on specific genetic subtypes: MDM2-amplified, myxoid, and CIC-rearranged sarcomas.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BTX-A51 (a kinase inhibitor taken orally)
What this could lead to: If it works, this could point toward a new treatment option for certain types of liposarcoma that have spread or come back.
What could go wrong: This is a very early (Phase 1) pilot study with only 24 people, so it is primarily checking safety and dosing. It may not show strong anti-cancer effects, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CIC-REARRANGED SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

CIC-rearranged sarcoma dedifferentiated liposarcoma liposarcoma myxoid liposarcoma well-differentiated liposarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CIC-REARRANGED SARCOMA LIPOSARCOMA MDM2 GENE AMPLIFICATION METASTATIC LIPOSARCOMA MYXOID LIPOSARCOMA RECURRENT LIPOSARCOMA UNRESECTABLE LIPOSARCOMA

New drug BTX-A51 tested in rare sarcomas

Summary

What this could mean

Get notified about this study

Conditions

As listed by the trial registrant

Contacts and locations

Locations

More trials for these conditions